The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

BACKGROUND: ER+/HER2− breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. METHODS: A total of 1702 postmenopausal ER+/HER2− breast cancer patients from two adju...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dubsky, P, Brase, J C, Jakesz, R, Rudas, M, Singer, C F, Greil, R, Dietze, O, Luisser, I, Klug, E, Sedivy, R, Bachner, M, Mayr, D, Schmidt, M, Gehrmann, M C, Petry, C, Weber, K E, Fisch, K, Kronenwett, R, Gnant, M, Filipits, M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3859949/
https://ncbi.nlm.nih.gov/pubmed/24157828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.671
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados